Johnson & Johnson (NYSE:JNJ) announced today that its set to provide 200 million doses of its COVID-19 vaccine candidate to Europe.
The European Commission, on behalf of the European Union, approved an advance purchase agreement in which J&J subsidiary Janssen Pharmaceutical, which is developing the vaccine candidate, would supply the doses to EU member states following approval or authorization.
Get the full story at our sister site, MassDevice.
Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
